PharmiWeb.com - Global Pharma News & Resources
10-Feb-2021

Explore Pulmonary Functions Test systems Market Demand 2020-2026

Summary

The global Pulmonary Functions Test systems market was valued at USD 2234.92 million in 2019 and is expected to reach USD 3557.15 million by the year 2026, at a CAGR of 6.93%.
Editor: Vinayak Patil Last Updated: 11-Feb-2021

The global Pulmonary Functions Test systems market was valued at USD 2234.92 million in 2019 and is expected to reach USD 3557.15 million by the year 2026, at a CAGR of 6.93%.

pulmonary function tests include various types of tests that check how well the lungs work. This test measures the amount of air our lungs can hold. This test comprises of series of tests that are used for detecting if there is an infection in the lungs that are fatal.

The number of people suffering from lung cancer due to excessive use of cigarette smoking. also, nowadays there is prevalence of lung cancer, old people population, obesities rising.  this factor drives the demand Pulmonary Functions Test systems Market

Doctors always recommend regular pulmonary function testing for people of all age groups. Furthermore, PFT is necessary for patients with existing lung dysfunction or lung diseases. This factor drives the market

Major Key Players Considered in the Market

  • CareFusion (BD),
  • MGC Diagnostic,
  • Data Sciences International,
  • Medline Industries,
  • Ganshorn,
  • 3M,
  • NSpire Health,
  • Schiller,
  • Morgan scientific,
  • CHEST,
  • NDD,
  • Vyaire Medical,
  • COSMED and many others.

The Pulmonary Functions Test systems market is segmented by Type

  • Complete PFT Systems
  • Portable PFT Systems

By Test Type

  • Spirometry,
  • Lung Volume,
  • Gas Exchange Testing,
  • Maximal Voluntary Ventilation,
  • Oxygen Titration Test
  • High Altitude Simulation Testing

by Application

  • Chronic Obstructive Pulmonary Disease,
  • Asthma,
  • Chronic Shortness of Breath
  • Restrictive Lung Disease

Regions and Countries Level Analysis:

  • USA
  • Europe
  • Japan
  • China
  • India
  • southeast Asia

Restrictive Lung Disease is accounted for the largest segment with more than half of the market share. In Test type segment, the Spirometry segment is accounted for the largest segment with a market share of 34.32%

The aging population is at a greater risk of suffering from pulmonary disorders. There are more old people population in North America. This factor increases the growth in Market